Oral versus combination mesalazine therapy in active ulcerative colitis: A double-blind, double-dummy, randomized multicentre study

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 2, 2001, Pages 251-256

  Vecchi, M ^a   Meucci, G ^b   Gionchetti, P ^c   Beltrami, M ^d   Di Maurizio, P ^e   Beretta, L ^f   Ganio, E ^g   Usai, P ^h   Campieri, M ^c   Fornaciari, G ^d   De Franchis, R ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b VALDUCE HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e FATEBENEFRATELLI HOSPITAL   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g Ospedale di Ivrea   (Italy)

^h Clinica Medica Aresu   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; ENDOSCOPY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0035126080     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00913.x     Document Type: Article

References (23)

1. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
2. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine in the treatment of mild to moderate ulcerative colitis relapse
3. Coated mesalazine (5 aminosalicylic acid) versus sulfasalazine in the treatment of active ulcerative colitis a randomized trial
4. Oral mesalamine (Asacol) for mildly to moderaltely active ulcerative colitis: A multicenter study
5. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial
6. Sulfasalazine revisited: A meta-analysis of five aminsalicylic acid in the treatment of ulcerative colitis
7. Treatment of ulcerative colitis with high dose 5 aminosalicylic acid enemas
8. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: A randomized, controlled trial
9. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis
10. Optimun dosage of 5-aminosalicylic acid as rectal enemas in patients with ulcerative colitis
11. Comparison of bismuth citrate and 5-aminosalicyilic acid enemas in distal ulcerative colitis. A controlled trial
12. Dose-ranging study of mesalamine (Pentasa) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentered placebo-controlled trial
13. Rectal aminosalicyilate therapy for distal ulcerative colitis. A meta-analysis
14. 5-Aminosalycilic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis
15. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: A randomised double blind placebo controlled multicentre study
16. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: A double-blind placebo-controlled trial
17. Comparison of the efficacy and safety of sulphasalaziene and mesalazines in the maintenance treatment of ulcerative colitis: A meta-analysis
18. Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn's disease
19. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis
20. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
21. Combined therapy with 5-Aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double-blind study
22. Double therapy for IBD better than single therapy? The issue is not how but how much
23. Oral delayedrelease mesalazine in the treatment of mild ulcerative colitis: A dose-ranging study